Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;2(1):3-9.
doi: 10.1177/2051013613507862.

Latest developments and future directions in dengue vaccines

Usa Thisyakorn  1 , Chule Thisyakorn  2
Affiliations
Review

Latest developments and future directions in dengue vaccines

Usa Thisyakorn et al. Ther Adv Vaccines. 2014 Jan.

Abstract

Dengue is a mosquito-borne disease which is currently an expanding global health problem. The disease is caused by four closely related viruses, the dengue virus. There are no specific dengue therapeutics and prevention is currently limited to vector control measures. Development of an effective tetravalent dengue vaccine would therefore represent a major advance in the control of the disease and is considered a high public health priority. While a licensed dengue vaccine is not yet available, the scope and intensity of dengue vaccine development has increased dramatically in the last decade. The uniqueness of the dengue viruses and the spectrum of disease resulting from infection have made dengue vaccine development difficult. Several vaccine candidates are currently being evaluated in clinical studies. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on chimeric yellow fever dengue virus, has progressed to phase III efficacy studies. Several other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates, are at earlier stages of clinical development. Additional technological approaches, such as virus-vectored and virus-like particle-based vaccines, are under evaluation in preclinical studies.

Keywords: Flavivirus; dengue fever; dengue infection; dengue vaccines; development; live-attenuated tetravalent vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

References

    1. Aihara H., Takasaki T., Toyosaki-Maeda T., Suzuki R., Okuno Y., Kurane I. (2000) T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine. Viral Immunol 13: 179–186 - PubMed
    1. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., et al. (2006) Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24: 335–344 - PubMed
    1. Arora U., Tyagi P., Swaminathan S., Khanna N. (2013) Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine 31: 873–878 - PubMed
    1. Balas C., Kennel A., Deauvieau F., Sodoyer R., Arnaud-Barbe N., Lang J., et al. (2011) Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1–4 vaccine virus strains. J Infect Dis 203: 103–108 - PMC - PubMed
    1. Beckett C., Tjaden J., Burgess T., Danko J., Tamminga C., Simmons M., et al. (2011) Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 29: 960–968 - PubMed